CliffBio
small molecule

INTERMEZZO

ZOLPIDEM TARTRATE

Loss of exclusivityAugust 2029latest FDA-listed patent expiry
CompanyPURDUE PHARMA PRODUCTS LP

Drug detail

Brand nameINTERMEZZO
Active ingredientZOLPIDEM TARTRATE
Strength3.5MG
Dosage formTABLET
RouteSUBLINGUAL
ModalitySmall molecule
FDA approvalNovember 2011
Marketing statusDISCN

Listed patents

PatentExpiresType
8242131August 2029use U-1266
7658945April 2027product

More from PURDUE PHARMA PRODUCTS LP

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INTERMEZZO patent cliff — loss of exclusivity August 2029 | CliffBio